Clinical ResearchInterventional CardiologyA Randomized Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft Lesions: The SOS (Stenting Of Saphenous Vein Grafts) Trial

[1]  E. Brilakis,et al.  Should bare metal or drug‐eluting stents be used during PCI of saphenous vein graft lesions: Waiting for Godot? , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  N. Weissman,et al.  Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. , 2008, The American journal of cardiology.

[3]  Peter L Duffy,et al.  Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. , 2008, JACC. Cardiovascular interventions.

[4]  G. Gioia,et al.  Lack of clinical long‐term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[5]  W. Little,et al.  Late outcomes of drug‐eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[6]  M. Pfisterer,et al.  Drug-Eluting Stents Compared with Bare Metal Stents Improve Late Outcome after Saphenous Vein Graft but Not after Large Native Vessel Interventions , 2008, Cardiology.

[7]  H. Loeb,et al.  Long‐term clinical outcomes of real‐world experience using sirolimus‐eluting stents in saphenous vein graft disease , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[8]  A. Santarelli,et al.  Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry). , 2008, The American journal of cardiology.

[9]  E. Brilakis,et al.  Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: a critical appraisal. , 2008, Journal of interventional cardiology.

[10]  A. J. O’Malley,et al.  Saphenous Vein Graft Stenting and Major Adverse Cardiac Events: A Predictive Model Derived From a Pooled Analysis of 3958 Patients , 2008, Circulation.

[11]  P. Barlis,et al.  Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions , 2008, Acute cardiac care.

[12]  Robert M. Minutello,et al.  Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. , 2007, Journal of interventional cardiology.

[13]  S. Ellis,et al.  Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. , 2007, The Journal of invasive cardiology.

[14]  Pierfrancesco Agostoni,et al.  Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. , 2007, Journal of the American College of Cardiology.

[15]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[16]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[17]  H. Kestler,et al.  Comparison of the slow-release polymerbased paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions , 2007, Clinical Research in Cardiology.

[18]  N. Bruining,et al.  Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. , 2006, Journal of the American College of Cardiology.

[19]  R. Hoffmann,et al.  Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study , 2006, Heart.

[20]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[21]  A. Shah,et al.  Drug‐eluting stenting is superior to bare metal stenting in saphenous vein grafts , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[22]  I. Iakovou,et al.  Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. , 2005, Journal of the American College of Cardiology.

[23]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[24]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[25]  J. Mehta,et al.  Percutaneous intervention on the saphenous vein bypass grafts—Long‐term outcomes , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[26]  K. Kent,et al.  Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. , 2006, The American journal of cardiology.